In brain cancers, concurrent mutations of BRAF and TERT promoter have been identified to be associated with tumor aggressiveness (Mistry et al., 2015; Matsumura et al., 2017; Mackay et al., 2018; Phillips et al., 2019). This evidence concerns the gene TERT and neoplasm.